

Dick de Zeeuw

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8825162/dick-de-zeeuw-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

540
papers

48,820
citations

92
h-index

212
g-index

584
ext. papers

57,115
ext. citations

8.7
avg, IF

7.21
L-index

#	Paper	IF	Citations
540	The impact of canagliflozin on the risk of neuropathy events: a post-hoc exploratory analysis of the CREDESCENCE trial. <i>Diabetes and Metabolism</i> , 2022 , 101331	5.4	0
539	The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A Analysis of the SONAR Randomized Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021 ,	6.9	1
538	Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDESCENCE trial. <i>American Heart Journal</i> , 2021 , 233, 141-148	4.9	10
537	Canagliflozin, serum magnesium and cardiovascular outcomes-Analysis from the CANVAS Program. <i>Endocrinology, Diabetes and Metabolism</i> , 2021 , 4, e00247	2.7	1
536	The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDESCENCE trial. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1652-1659	6.7	3
535	Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS Program and CREDESCENCE trial. <i>Cardiovascular Research</i> , 2021 ,	9.9	2
534	Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDESCENCE Trial. <i>Circulation</i> , 2021 , 143, 1735-1749	16.7	19
533	Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. <i>Lancet, The</i> , 2021 , 397, 1625-1636	40	101
532	Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDESCENCE Trial. <i>American Journal of Kidney Diseases</i> , 2021 ,	7.4	7
531	Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDESCENCE Trial and Meta-Analysis. <i>Stroke</i> , 2021 , 52, 1545-1556	6.7	11
530	Perspectives on a Way Forward to Implementation of Precision Medicine in Patients With Diabetic Kidney Disease; Results of a Stakeholder Consensus-Building Meeting. <i>Frontiers in Pharmacology</i> , 2021 , 12, 662642	5.6	1
529	129-LB: Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex in the CREDESCENCE Trial. <i>Diabetes</i> , 2021 , 70, 129-LB	0.9	
528	133-LB: Canagliflozin Improves Cardiovascular and Renal Outcomes across Broad Geographic Regions: Results from CREDESCENCE. <i>Diabetes</i> , 2021 , 70, 133-LB	0.9	
527	131-LB: The Impact of Canagliflozin on the Risk of Neuropathy Events: Results from the CREDESCENCE Trial. <i>Diabetes</i> , 2021 , 70, 131-LB	0.9	
526	Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 382-390	6.7	20
525	Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program. <i>American Journal of Kidney Diseases</i> , 2021 , 77, 23-34.e1	7.4	12
524	New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction. <i>Kidney International</i> , 2021 , 99, 346-349	9.9	10

523	Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. <i>Kidney International</i> , 2021 , 99, 999-1009	8.9	23
522	The International Society of Nephrology Advancing Clinical Trials (ISN-ACT) Network: current activities and future goals. <i>Kidney International</i> , 2021 , 99, 551-554	9.9	1
521	Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 109, 1631-1638	6.1	0
520	Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 561-568	6.7	6
519	Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program. <i>CKJ: Clinical Kidney Journal</i> , 2021 , 14, 1396-1402	4.5	8
518	A novel drug response score more accurately predicts renoprotective drug effects than existing renal risk scores. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2021 , 12, 2042018820974191	4.5	1
517	Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021 , 16, 384-395	6.9	12
516	Diminished antiproteinuric effect of the angiotensin receptor blocker losartan during high potassium intake in patients with CKD. <i>CKJ: Clinical Kidney Journal</i> , 2021 , 14, 2170-2176	4.5	
515	Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 2707-2715	6.7	0
514	Large Between-Patient Variability in eGFR Decline before Clinical Trial Enrollment and Impact on Atrasentan's Efficacy: A Analysis from the SONAR Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2021 , 32, 2731-2734	12.7	0
513	Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA, disease duration and treatment intensity: results from the CANVAS Program. <i>Diabetologia</i> , 2021 , 64, 2402-2414	10.3	2
512	Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2021 , 32, 2900-2911	12.7	1
511	Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. <i>Lancet, The</i> , 2021 , 398, 1053-1064	4.0	27
510	Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021 ,	6.9	3
509	Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020 , 31, 1128-1139	12.7	51
508	Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes. <i>Kidney International</i> , 2020 , 98, 769-777	9.9	26
507	EFFECTS OF CANAGLIFLOZIN ON STROKE IN THE CREDENCE TRIAL. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 215	15.1	2
506	Time for clinical decision support systems tailoring individual patient therapy to improve renal and cardiovascular outcomes in diabetes and nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35, ii38-ii42	4.3	7

505	Prognostic imaging biomarkers for diabetic kidney disease (iBEAT): study protocol. <i>BMC Nephrology</i> , 2020 , 21, 242	2.7	4
504	Reply: Mediators of the Effects of Canagliflozin on Heart Failure: Central Role of the Cardiorenal Axis. <i>JACC: Heart Failure</i> , 2020 , 8, 427	7.9	
503	Atrasentan in patients with diabetes and chronic kidney disease - Authors' reply. <i>Lancet, The</i> , 2020 , 395, 270	4.0	1
502	Discontinuation of RAAS Inhibition in Children with Advanced CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020 , 15, 625-632	6.9	10
501	27-OR: Effect of Canagliflozin on Total Hospitalization for Heart Failure Events in Patients with Type 2 Diabetes and Chronic Kidney Disease. <i>Diabetes</i> , 2020 , 69, 27-OR	0.9	1
500	2-OR: Impact of N Terminal Pro B-Type Natriuretic Peptide and High Sensitivity Cardiac Troponin on the Prediction of Death and Cardiovascular Events in High-Risk Patients with Type 2 Diabetes. <i>Diabetes</i> , 2020 , 69, 2-OR	0.9	
499	Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes. <i>JACC: Heart Failure</i> , 2020 , 8, 57-66	7.9	44
498	Pathophysiology of Proteinuria: Albuminuria as a Target for Treatment 2020 , 211-224		
497	Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c. <i>Circulation</i> , 2020 , 141, 407-410	16.7	62
496	Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 530-539	6.7	10
495	Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Analysis from the CREDENCE Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020 , 31, 2925-2936	12.7	30
494	International consensus definitions of clinical trial outcomes for kidney failure: 2020. <i>Kidney International</i> , 2020 , 98, 849-859	9.9	19
493	Effects of Canagliflozin in Patients with Baseline eGFR. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020 , 15, 1705-1714	6.9	30
492	Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program. <i>Journal of the American Society of Nephrology: JASN</i> , 2020 , 31, 2446-2456	12.7	5
491	The future of Diabetic Kidney Disease management: reducing the unmet need. <i>Journal of Nephrology</i> , 2020 , 33, 1163-1169	4.8	3
490	NT-proBNP by Itself Predicts Death and Cardiovascular Events in High-Risk Patients With Type 2 Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2020 , 9, e017462	6	15
489	Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency. <i>American Journal of Kidney Diseases</i> , 2020 , 75, 84-104	7.4	124
488	Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. <i>Kidney International</i> , 2019 , 96, 170-179	9.9	5

487	Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019 , 139, 2591-2593	16.7	89
486	Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program. <i>Diabetologia</i> , 2019 , 62, 926-938	10.3	65
485	Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2019 , 393, 1937-1947	4.0	209
484	Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. <i>New England Journal of Medicine</i> , 2019 , 380, 2295-2306	59.2	2060
483	Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program. <i>Diabetologia</i> , 2019 , 62, 1854-1867	10.3	29
482	Association between individual cholesterol and proteinuria response and exposure to atorvastatin or rosuvastatin. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 2635-2642	6.7	1
481	Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. <i>Circulation</i> , 2019 , 140, 739-750	16.7	140
480	Renal hyperfiltration defined by high estimated glomerular filtration rate: A risk factor for cardiovascular disease and mortality. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 2368-2383	6.7	26
479	(Clinical) Trial and Error in Diabetic Nephropathy 2019 , 415-431		
478	1216-P: The Effects of Canagliflozin on Uric Acid and Gout in Patients with Type 2 Diabetes in the CANVAS Program. <i>Diabetes</i> , 2019 , 68, 1216-P	0.9	1
477	1203-P: Cause of Hospitalizations in Patients with Type 2 Diabetes Mellitus (T2DM) in the CANVAS Program. <i>Diabetes</i> , 2019 , 68, 1203-P	0.9	
476	Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program. <i>Journal of the American Society of Nephrology: JASN</i> , 2019 , 30, 2229-2242	12.7	57
475	The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program. <i>Lancet Rheumatology, The</i> , 2019 , 1, e220-e228	14.2	20
474	Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials. <i>Nephrology Dialysis Transplantation</i> , 2019 , 34, 1699-1706	4.3	3
473	Effects of Dapagliflozin on Circulating Markers of Phosphate Homeostasis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019 , 14, 66-73	6.9	42
472	Canagliflozin and Stroke in Type 2 Diabetes Mellitus. <i>Stroke</i> , 2019 , 50, 396-404	6.7	32
471	Future and Novel Compounds in the Treatment of Diabetic Nephropathy 2019 , 515-539		2
470	Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. <i>Lancet Diabetes and Endocrinology, the</i> , 2019 , 7, 115-127	18.1	114

469	Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 128-139	18.1	119
468	Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium. <i>American Journal of Kidney Diseases</i> , 2019 , 73, 206-217	7.4	25
467	Guidelines and clinical practice at the primary level of healthcare in patients with type 2 diabetes mellitus with and without kidney disease in five European countries. <i>Diabetes and Vascular Disease Research</i> , 2019 , 16, 47-56	3.3	9
466	A Prospective Cohort Study in Patients with Type 2 Diabetes Mellitus for Validation of Biomarkers (PROVALID) - Study Design and Baseline Characteristics. <i>Kidney and Blood Pressure Research</i> , 2018 , 43, 181-190	3.1	14
465	Determining the optimal dose of atrasentan by evaluating the exposure-response relationships of albuminuria and bodyweight. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2019-2022	6.7	9
464	Baseline characteristics and enrichment results from the SONAR trial. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1829-1835	6.7	22
463	Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1369-1376	6.7	49
462	Individual variability in response to renin angiotensin aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: A primary care cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1377-1383	6.7	6
461	Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis. <i>European Heart Journal</i> , 2018 , 39, 1535-1542	9.5	118
460	Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program. <i>Circulation</i> , 2018 , 138, 458-468	16.7	262
459	Does SGLT2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition?. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 224-227	6.7	12
458	Early Proteinuria Lowering by Angiotensin-Converting Enzyme Inhibition Predicts Renal Survival in Children with CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2018 , 29, 2225-2233	12.7	55
457	N-terminal pro-brain natriuretic peptide (NT-proBNP) predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2899-2904	6.7	7
456	Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. <i>Lancet Diabetes and Endocrinology</i> , 2018 , 6, 691-704	18.1	304
455	Consistent Outcomes with Canagliflozin (CANA) in Patients with Type 2 Diabetes across Geographic Regions Results from the CANagliflozin CardioVascular Assessment Study (CANVAS) Program. <i>Diabetes</i> , 2018 , 67, 1193-P	0.9	1
454	Relatively Consistent Effects of Canagliflozin (CANA) on Outcomes Regardless of Baseline HbA1c in the CANagliflozin CardioVascular Assessment Study (CANVAS) Program. <i>Diabetes</i> , 2018 , 67, 1191-P	0.9	
453	Improved Cardiovascular and Renal Outcomes in the CANagliflozin CardioVascular Assessment Study (CANVAS) Program Irrespective of Baseline (BL) Body Mass Index (BMI). <i>Diabetes</i> , 2018 , 67, 1206-P ^{0.9}		
452	Three-question set from Michigan Neuropathy Screening Instrument adds independent prognostic information on cardiovascular outcomes: analysis of ALTITUDE trial. <i>Diabetologia</i> , 2018 , 61, 581-588	10.3	10

451	Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. <i>Kidney International</i> , 2018 , 93, 1000-1007	9.9	21
450	Longitudinal Estimated GFR Trajectories in Patients With and Without Type 2 Diabetes and Nephropathy. <i>American Journal of Kidney Diseases</i> , 2018 , 71, 91-101	7.4	38
449	Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). <i>Circulation</i> , 2018 , 137, 323-334	16.7	284
448	Renal trials in diabetes need a platform: time for a global approach?. <i>Lancet Diabetes and Endocrinology</i> , 2018 , 6, 356-358	18.1	8
447	Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial. <i>Lancet Diabetes and Endocrinology</i> , 2018 , 6, 925-933	18.1	20
446	Treating diabetic complications; from large randomized clinical trials to precision medicine. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20 Suppl 3, 3-5	6.7	5
445	How to measure and monitor albuminuria in healthy toddlers?. <i>PLoS ONE</i> , 2018 , 13, e0199309	3.7	1
444	Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function. <i>Circulation</i> , 2018 , 138, 1537-1550	16.7	149
443	Systems Biology-Derived Biomarkers to Predict Progression of Renal Function Decline in Type 2 Diabetes. <i>Diabetes Care</i> , 2017 , 40, 391-397	14.6	33
442	Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 387-393	6.7	101
441	Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 926-935	6.7	78
440	Comparison of exposure response relationship of atrasentan between North American and Asian populations. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 545-552	6.7	2
439	ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD. <i>American Journal of Kidney Diseases</i> , 2017 , 70, 522-531	7.4	7
438	Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017 , 377, 644-657	59.2	3789
437	The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 1363-1370	6.7	64
436	Variability in response to albuminuria-lowering drugs: true or random?. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 1197-1204	3.8	14
435	The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 749-753	6.7	14
434	Pooled Analysis of Multiple Crossover Trials To Optimize Individual Therapy Response to Renin-Angiotensin-Aldosterone System Intervention. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017 , 12, 1804-1813	6.9	7

433	Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Drugs in R and D</i> , 2017 , 17, 441-448 ^{3,4}		6
432	Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017 , 12, 1595-1600	6.9	2
431	The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CRENDENCE) Study Rationale, Design, and Baseline Characteristics. <i>American Journal of Nephrology</i> , 2017 , 46, 462-472	4.6	149
430	Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study. <i>Nephrology Dialysis Transplantation</i> , 2017 , 32, 1866-1873	4.3	47
429	Urine Albumin-Creatinine Ratio Versus Albumin Excretion for Albuminuria Staging: A Prospective Longitudinal Cohort Study. <i>American Journal of Kidney Diseases</i> , 2016 , 67, 70-8	7.4	12
428	Novel anti-inflammatory drugs for the treatment of diabetic kidney disease. <i>Diabetologia</i> , 2016 , 59, 1621-3	6.3	14
427	Blood pressure-lowering effects of sulodexide depend on albuminuria severity: post hoc analysis of the sulodexide microalbuminuria and macroalbuminuria studies. <i>British Journal of Clinical Pharmacology</i> , 2016 , 82, 1351-1357	3.8	9
426	Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP). <i>American Journal of Kidney Diseases</i> , 2016 , 68, 371-80	7.4	37
425	Comparison of urine collection methods for albuminuria assessment in young children. <i>Clinica Chimica Acta</i> , 2016 , 458, 120-3	6.2	5
424	Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2016 , 4, 309-17	18.1	31
423	Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers. <i>European Journal of Preventive Cardiology</i> , 2016 , 23, 758-68	3.9	26
422	Individual long-term albuminuria exposure during angiotensin receptor blocker therapy is the optimal predictor for renal outcome. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, 1471-7	4.3	15
421	Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP). <i>American Journal of Kidney Diseases</i> , 2016 , 67, 576-84	7.4	16
420	Prevalence and distribution of (micro)albuminuria in toddlers. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, 1686-92	4.3	11
419	Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial. <i>Diabetes, Obesity and Metabolism</i> , 2016 , 18, 169-77	6.7	44
418	Unmet need in diabetic nephropathy: failed drugs or trials?. <i>Lancet Diabetes and Endocrinology</i> , 2016 , 4, 638-640	18.1	33
417	Renal endothelial function is associated with the anti-proteinuric effect of ACE inhibition in 5/6 nephrectomized rats. <i>American Journal of Physiology - Renal Physiology</i> , 2016 , 310, F1047-53	4.3	3
416	Determining the Optimal Protocol for Measuring an Albuminuria Class Transition in Clinical Trials in Diabetic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2016 , 27, 3405-3412	12.7	7

415	ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—the Berlin Roadmap. <i>Kidney International Reports</i> , 2016 , 1, 327-339	4.1	1
414	Plasma calcidiol, calcitriol, and parathyroid hormone and risk of new onset heart failure in a population-based cohort study. <i>ESC Heart Failure</i> , 2016 , 3, 189-197	3.7	19
413	Early renin-angiotensin system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2016 , 18, 64-71	6.7	46
412	Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2016 , 18, 82-91	6.7	65
411	Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetes. <i>Nephrology Dialysis Transplantation</i> , 2015 , 30 Suppl 4, iv86-95	4.3	29
410	Plasma 1,25-Dihydroxyvitamin D and the Risk of Developing Hypertension: The Prevention of Renal and Vascular End-Stage Disease Study. <i>Hypertension</i> , 2015 , 66, 563-70	8.5	24
409	A panel of novel biomarkers representing different disease pathways improves prediction of renal function decline in type 2 diabetes. <i>PLoS ONE</i> , 2015 , 10, e0120995	3.7	47
408	Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial). <i>American Journal of Kidney Diseases</i> , 2015 , 66, 458-8	7.4	30
407	Number and frequency of albuminuria measurements in clinical trials in diabetic nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015 , 10, 410-6	6.9	19
406	The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial. <i>Lancet Diabetes and Endocrinology</i> , 2015 , 3, 687-96	18.1	173
405	The paradox created by commenting on large clinical trial results. <i>Diabetes, Obesity and Metabolism</i> , 2015 , 17, 1-2	6.7	
404	The glycocalyx—linking albuminuria with renal and cardiovascular disease. <i>Nature Reviews Nephrology</i> , 2015 , 11, 667-76	14.9	99
403	Plasma Vitamin D Level and Change in Albuminuria and eGFR According to Sodium Intake. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015 , 10, 2119-27	6.9	28
402	Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial. <i>Diabetes Therapy</i> , 2015 , 6, 289-302	3.6	32
401	Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015 , 10, 1568-74	6.9	28
400	Albuminuria 2015 , 663-673		1
399	Renal end points in clinical trials of kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2015 , 24, 284-9	3.5	10
398	The blood pressure lowering potential of sulodexide—a systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2015 , 80, 1245-53	3.8	21

397	Plasma proteomics classifiers improve risk prediction for renal disease in patients with hypertension or type 2 diabetes. <i>Journal of Hypertension</i> , 2015 , 33, 2123-32	1.9	21
396	The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers. <i>British Journal of Clinical Pharmacology</i> , 2015 , 80, 678-86	3.8	32
395	The Role of Patients' Age on Their Preferences for Choosing Additional Blood Pressure-Lowering Drugs: A Discrete Choice Experiment in Patients with Diabetes. <i>PLoS ONE</i> , 2015 , 10, e0139755	3.7	9
394	FP272A PANEL OF NOVEL BIOMARKERS REPRESENTING DIFFERENT DISEASE PATHWAYS IMPROVES PREDICTION OF RENAL FUNCTION DECLINE IN TYPE 2 DIABETES. <i>Nephrology Dialysis Transplantation</i> , 2015 , 30, iii158-iii158	4.3	
393	Relevance of correction for drift and day-to-day variation in cystatin C measurement: a post-hoc analysis of the PREVEND cohort, with independent replication in the ESTHER cohort. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015 , 53, 1381-90	5.9	8
392	Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. <i>Diabetes Care</i> , 2015 , 38, 403-11	14.6	171
391	Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. <i>Lancet Diabetes and Endocrinology</i> , 2015 , 3, 181-90	18.1	87
390	Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2015 , 26, 2055-64	12.7	158
389	Pathogenesis, Pathophysiology, and Treatment of Diabetic Nephropathy 2014 , 222-234		1
388	Medication beliefs, treatment complexity, and non-adherence to different drug classes in patients with type 2 diabetes. <i>Journal of Psychosomatic Research</i> , 2014 , 76, 134-8	4.1	84
387	The effect of RAAS blockade on the progression of diabetic nephropathy. <i>Nature Reviews Nephrology</i> , 2014 , 10, 77-87	14.9	100
386	A novel approach for establishing cardiovascular drug efficacy. <i>Nature Reviews Drug Discovery</i> , 2014 , 13, 942	64.1	17
385	The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2014 , 25, 1083-93	12.7	168
384	Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial. <i>American Journal of Kidney Diseases</i> , 2014 , 64, 714-22	7.4	54
383	Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. <i>Journal of Cardiac Failure</i> , 2014 , 20, 953-8	3.3	115
382	The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial. <i>European Journal of Preventive Cardiology</i> , 2014 , 21, 299-309	3.9	28
381	Do diabetic kidneys deserve a lifestyle change?. <i>Lancet Diabetes and Endocrinology</i> , 2014 , 2, 769-70	18.1	2
380	Construct and concurrent validity of a patient-reported adverse drug event questionnaire: a cross-sectional study. <i>Health and Quality of Life Outcomes</i> , 2014 , 12, 103	3	10

379	Urine and plasma metabolites predict the development of diabetic nephropathy in individuals with Type 2 diabetes mellitus. <i>Diabetic Medicine</i> , 2014 , 31, 1138-47	3.5	94
378	Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT). <i>American Journal of Kidney Diseases</i> , 2014 , 63, 244-50	7.4	41
377	The validity of a patient-reported adverse drug event questionnaire using different recall periods. <i>Quality of Life Research</i> , 2014 , 23, 2439-45	3.7	7
376	Improving clinical trial efficiency by biomarker-guided patient selection. <i>Trials</i> , 2014 , 15, 103	2.8	12
375	The importance of short-term off-target effects in estimating the long-term renal and cardiovascular protection of angiotensin receptor blockers. <i>Clinical Pharmacology and Therapeutics</i> , 2014 , 95, 208-15	6.1	22
374	Bilirubin and progression of nephropathy in type 2 diabetes: a post hoc analysis of RENAAL with independent replication in IDNT. <i>Diabetes</i> , 2014 , 63, 2845-53	0.9	43
373	The authors reply. <i>Kidney International</i> , 2014 , 86, 1270	9.9	
372	Microalbuminuria: target for renoprotective therapy PRO. <i>Kidney International</i> , 2014 , 86, 40-9	9.9	48
371	New renal guidelines; is more better?. <i>Nephrology Dialysis Transplantation</i> , 2014 , 29, 720-1	4.3	
370	Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. <i>American Journal of Nephrology</i> , 2014 , 40, 64-74	4.6	89
369	Relative risks of chronic kidney disease for mortality and end-stage renal disease across races are similar. <i>Kidney International</i> , 2014 , 86, 819-27	9.9	52
368	A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers. <i>European Journal of Preventive Cardiology</i> , 2014 , 21, 434-41	3.9	18
367	GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. <i>American Journal of Kidney Diseases</i> , 2014 , 64, 821-35	7.4	300
366	Effects of lowering LDL cholesterol on progression of kidney disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2014 , 25, 1825-33	12.7	108
365	Predictors of congestive heart failure after treatment with an endothelin receptor antagonist. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014 , 9, 490-8	6.9	19
364	Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia. <i>BMJ Open Diabetes Research and Care</i> , 2014 , 2, e000011	4.5	21
363	The use of surrogate endpoints in regulating medicines for cardio-renal disease: opinions of stakeholders. <i>PLoS ONE</i> , 2014 , 9, e108722	3.7	9
362	Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON). <i>American Journal of Nephrology</i> , 2013 , 37, 212-22	4.6	67

361	Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial. <i>American Heart Journal</i> , 2013 , 166, 217-223.e11	4.9	256
360	Development and Initial Validation of a Patient-Reported Adverse Drug Event Questionnaire. <i>Drug Safety</i> , 2013 , 36, 765-77	5.1	20
359	Creatinine excretion rate and mortality in type 2 diabetes and nephropathy. <i>Diabetes Care</i> , 2013 , 36, 1489-94	14.6	26
358	LDL cholesterol in CKD--to treat or not to treat?. <i>Kidney International</i> , 2013 , 84, 451-6	9.9	29
357	A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus. <i>Diabetologia</i> , 2013 , 56, 259-67	10.3	117
356	Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. <i>New England Journal of Medicine</i> , 2013 , 369, 2492-503	59.2	662
355	Is albuminuria screening and treatment optimal in patients with type 2 diabetes in primary care? Observational data of the GIANTT cohort. <i>Nephrology Dialysis Transplantation</i> , 2013 , 28, 706-15	4.3	12
354	Screening for albuminuria with subsequent screening for hypertension and hypercholesterolaemia identifies subjects in whom treatment is warranted to prevent cardiovascular events. <i>Nephrology Dialysis Transplantation</i> , 2013 , 28, 2805-15	4.3	14
353	PS3 - 5. Do treatment quality indicators predict cardiovascular outcomes in patients with diabetes?. <i>Nederlands Tijdschrift Voor Diabetologie</i> , 2013 , 11, 142-142	0	
352	PS11 - 1. Longitudinal eGFR trajectories in patients with type 2 diabetes. <i>Nederlands Tijdschrift Voor Diabetologie</i> , 2013 , 11, 162-162	0	
351	Treatment quality indicators predict short-term outcomes in patients with diabetes: a prospective cohort study using the GIANTT database. <i>BMJ Quality and Safety</i> , 2013 , 22, 339-47	5.4	13
350	Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2013 , 15, 853-62	6.7	501
349	Novel drugs and intervention strategies for the treatment of chronic kidney disease. <i>British Journal of Clinical Pharmacology</i> , 2013 , 76, 536-50	3.8	32
348	Baseline characteristics in the Bardoxolone methyl Evaluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal events (BEACON) trial. <i>Nephrology Dialysis Transplantation</i> , 2013 , 28, 2841-50	4.3	18
347	Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study. <i>Nephrology Dialysis Transplantation</i> , 2013 , 28, 2260-8	4.3	26
346	High-sensitivity troponin T predicts worsening of albuminuria in hypertension; results of a nested case-control study with confirmation in diabetes. <i>Journal of Hypertension</i> , 2013 , 31, 805-12	1.9	19
345	Association between performance measures and glycemic control among patients with diabetes in a community-wide primary care cohort. <i>Medical Care</i> , 2013 , 51, 172-9	3.1	12
344	Predictors of progression in albuminuria in the general population: results from the PREVEND cohort. <i>PLoS ONE</i> , 2013 , 8, e61119	3.7	16

343	Do treatment quality indicators predict cardiovascular outcomes in patients with diabetes?. <i>PLoS ONE</i> , 2013 , 8, e78821	3.7	11
342	Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database. <i>American Journal of Kidney Diseases</i> , 2012 , 59, 75-83	7.4	139
341	Effect of frozen storage on urinary concentration of kidney damage markers. <i>American Journal of Kidney Diseases</i> , 2012 , 59, 586-9	7.4	16
340	Validity of biomarkers predicting onset or progression of nephropathy in patients with Type 2 diabetes: a systematic review. <i>Diabetic Medicine</i> , 2012 , 29, 567-77	3.5	49
339	Cardiorenal end points in a trial of aliskiren for type 2 diabetes. <i>New England Journal of Medicine</i> , 2012 , 367, 2204-13	59.2	893
338	Albuminuria, estimated GFR, traditional risk factors, and incident cardiovascular disease: the PREVEND (Prevention of Renal and Vascular Endstage Disease) study. <i>American Journal of Kidney Diseases</i> , 2012 , 60, 804-11	7.4	57
337	Influence of age on the prognostic value of mid-regional pro-adrenomedullin in the general population. <i>Heart</i> , 2012 , 98, 1348-53	5.1	24
336	Growth-differentiation factor 15 predicts worsening of albuminuria in patients with type 2 diabetes. <i>Diabetes Care</i> , 2012 , 35, 2340-6	14.6	40
335	Differential effects of comorbidity on antihypertensive and glucose-regulating treatment in diabetes mellitus--a cohort study. <i>PLoS ONE</i> , 2012 , 7, e38707	3.7	23
334	The geographical distribution of leadership in globalized clinical trials. <i>PLoS ONE</i> , 2012 , 7, e45984	3.7	26
333	PS12 - 60. Not all performance measures of diabetes management predict better glycemic control. <i>Nederlands Tijdschrift Voor Diabetologie</i> , 2012 , 10, 140-141	0	
332	PS12 Contd - 62. Prescribing of aliskiren in practice: findings from the GIANTT diabetes. <i>Nederlands Tijdschrift Voor Diabetologie</i> , 2012 , 10, 142-143	0	
331	Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy. <i>Nature Reviews Nephrology</i> , 2012 , 8, 691-9	14.9	24
330	Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. <i>Kidney International</i> , 2012 , 82, 330-7	9.9	159
329	Comparison of midregional pro-A-type natriuretic peptide and the N-terminal pro-B-type natriuretic peptide for predicting mortality and cardiovascular events. <i>Clinical Chemistry</i> , 2012 , 58, 293-7	5.5	22
328	Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2012 , 23, 123-30	12.7	116
327	Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2012 , 13, 387-93	3	45
326	An initial reduction in serum uric acid during angiotensin receptor blocker treatment is associated with cardiovascular protection: a post-hoc analysis of the RENAAL and IDNT trials. <i>Journal of Hypertension</i> , 2012 , 30, 1022-8	1.9	18

325	Comparing adverse event rates of oral blood glucose-lowering drugs reported by patients and healthcare providers: a post-hoc analysis of observational studies published between 1999 and 2011. <i>Drug Safety</i> , 2011 , 34, 1191-202	5.1	10
324	Omics-bioinformatics in the context of clinical data. <i>Methods in Molecular Biology</i> , 2011 , 719, 479-97	1.4	13
323	Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. <i>Kidney International</i> , 2011 , 79, 1331-40	9.9	468
322	An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. <i>Kidney International</i> , 2011 , 80, 282-7	9.9	217
321	Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT). <i>American Heart Journal</i> , 2011 , 162, 748-755.e3	4.9	54
320	Paricalcitol for reduction of albuminuria in diabetes [Authors' reply]. <i>Lancet, The</i> , 2011 , 377, 636-637	4.0	4
319	The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. <i>Lancet, The</i> , 2011 , 377, 2181-92	4.0	1627
318	A longitudinal study examining adherence to guidelines in diabetes care according to different definitions of adequacy and timeliness. <i>PLoS ONE</i> , 2011 , 6, e24278	3.7	4.0
317	Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. <i>American Journal of Kidney Diseases</i> , 2011 , 58, 729-36	7.4	89
316	Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. <i>Diabetologia</i> , 2011 , 54, 44-50	10.3	65
315	High serum potassium levels after losartan can reflect more severe renal disease. Reply to Gonçalves AR, El Nahas AM [letter]. <i>Diabetologia</i> , 2011 , 54, 2965-2967	10.3	3
314	A review of methods used in assessing non-serious adverse drug events in observational studies among type 2 diabetes mellitus patients. <i>Health and Quality of Life Outcomes</i> , 2011 , 9, 83	3	16
313	Gene therapy with adenovirus-delivered indoleamine 2,3-dioxygenase improves renal function and morphology following allogeneic kidney transplantation in rat. <i>Journal of Gene Medicine</i> , 2011 , 13, 373-81	3.5	17
312	Comment on: Ekinçi et al. Dietary salt intake and mortality in patients with type 2 diabetes. <i>Diabetes Care</i> 2011;34:703-709. <i>Diabetes Care</i> , 2011 , 34, e124; author reply e125	14.6	3
311	Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. <i>Hypertension</i> , 2011 , 58, 2-7	8.5	129
310	Drug-induced changes in risk/biomarkers and their relationship with renal and cardiovascular long-term outcome in patients with diabetes. <i>Clinical Chemistry</i> , 2011 , 57, 186-95	5.5	2
309	Initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trial. <i>Diabetes Care</i> , 2011 , 34, 2078-83	14.6	48
308	Monitoring kidney function and albuminuria in patients with diabetes. <i>Diabetes Care</i> , 2011 , 34 Suppl 2, S325-9	14.6	33

307	Unmet need in renal protection--do we need a more comprehensive approach?. <i>Contributions To Nephrology</i> , 2011 , 171, 157-160	1.6	18
306	ONTARGET still OFF-TARGET?. <i>Circulation</i> , 2011 , 123, 1049-51	16.7	7
305	Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. <i>European Heart Journal</i> , 2011 , 32, 1493-9	9.5	99
304	Need for better diabetes treatment for improved renal outcome. <i>Kidney International</i> , 2011 , S28-32	9.9	41
303	Review: relation between quality-of-care indicators for diabetes and patient outcomes: a systematic literature review. <i>Medical Care Research and Review</i> , 2011 , 68, 263-89	3.7	63
302	The kidney in type 2 diabetes therapy. <i>Review of Diabetic Studies</i> , 2011 , 8, 392-402	3.6	58
301	Erythropoietic response and outcomes in kidney disease and type 2 diabetes. <i>New England Journal of Medicine</i> , 2010 , 363, 1146-55	59.2	344
300	Effect of the urotensin receptor antagonist palosuran in hypertensive patients with type 2 diabetic nephropathy. <i>Hypertension</i> , 2010 , 55, 1206-9	8.5	32
299	Comparison of different measures of urinary protein excretion for prediction of renal events. <i>Journal of the American Society of Nephrology: JASN</i> , 2010 , 21, 1355-60	12.7	114
298	Renal vascular dysfunction precedes the development of renal damage in the hypertensive Fawn-Hooded rat. <i>American Journal of Physiology - Renal Physiology</i> , 2010 , 298, F625-33	4.3	28
297	N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population. <i>European Heart Journal</i> , 2010 , 31, 120-7	9.5	92
296	Selection on albuminuria enhances the efficacy of screening for cardiovascular risk factors. <i>Nephrology Dialysis Transplantation</i> , 2010 , 25, 3560-8	4.3	13
295	Debate: PRO position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial?. <i>American Journal of Nephrology</i> , 2010 , 31, 458-61; discussion 468	4.6	31
294	Composite renal endpoints: was ACCOMPLISH accomplished?. <i>Lancet, The</i> , 2010 , 375, 1140-2	4.0	33
293	Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. <i>Lancet, The</i> , 2010 , 376, 1543-51	4.0	522
292	Rebuttal: PRO Position. Should Microalbuminuria Ever Be Considered as a Renal Endpoint in Any Clinical Trial. <i>American Journal of Nephrology</i> , 2010 , 31, 466-467	4.6	10
291	Identifying targets to improve treatment in type 2 diabetes; the Groningen Initiative to aNalyse Type 2 diabetes Treatment (GIANTT) observational study. <i>Pharmacoepidemiology and Drug Safety</i> , 2010 , 19, 1078-86	2.6	7
290	Increased Levels of Urinary Albumin: A Cardiovascular Risk Factor and a Target for Treatment 2010 , 105-116		

289	Screening for albuminuria identifies individuals at increased renal risk. <i>Journal of the American Society of Nephrology: JASN</i> , 2009 , 20, 852-62	12.7	109
288	Reducing cardiovascular risk: protecting the kidney. <i>European Heart Journal Supplements</i> , 2009 , 11, F39-F46		2
287	First morning voids are more reliable than spot urine samples to assess microalbuminuria. <i>Journal of the American Society of Nephrology: JASN</i> , 2009 , 20, 436-43	12.7	172
286	The selective vitamin D receptor activator for albuminuria lowering (VITAL) study: study design and baseline characteristics. <i>American Journal of Nephrology</i> , 2009 , 30, 280-6	4.6	29
285	Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. <i>Nephrology Dialysis Transplantation</i> , 2009 , 24, 1663-71	4.3	245
284	High protein intake associates with cardiovascular events but not with loss of renal function. <i>Journal of the American Society of Nephrology: JASN</i> , 2009 , 20, 1797-804	12.7	59
283	Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>American Journal of Kidney Diseases</i> , 2009 , 54, 59-69	7.4	48
282	Albuminuria: what can we expect from the determination of nonimmunoreactive albumin?. <i>Current Hypertension Reports</i> , 2009 , 11, 111-7	4.7	7
281	Alkalinization of urine samples preserves albumin concentrations during prolonged frozen storage in patients with diabetes mellitus. <i>Diabetic Medicine</i> , 2009 , 26, 556-9	3.5	15
280	Renal failure induces telomere shortening in the rat heart. <i>Netherlands Heart Journal</i> , 2009 , 17, 190-4	2.2	8
279	A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. <i>New England Journal of Medicine</i> , 2009 , 361, 2019-32	59.2	1695
278	Dual renin-angiotensin system blockade and kidney disease. <i>Journal of the American College of Cardiology</i> , 2009 , 54, 278-9; author reply 279-80	15.1	10
277	Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. <i>Lancet, The</i> , 2009 , 373, 1009-15	4.0	302
276	Albuminuria in heart failure: what do we really know?. <i>Current Opinion in Cardiology</i> , 2009 , 24, 148-54	2.1	16
275	Renal and cardio-protective effects of direct renin inhibition: a systematic literature review. <i>Journal of Hypertension</i> , 2009 , 27, 2321-31	1.9	21
274	Renal endothelial function and blood flow predict the individual susceptibility to adriamycin-induced renal damage. <i>Nephrology Dialysis Transplantation</i> , 2009 , 24, 413-20	4.3	9
273	Selective cyclooxygenase-2 (COX-2) inhibition reduces proteinuria in renal patients. <i>Nephrology Dialysis Transplantation</i> , 2009 , 24, 1182-9	4.3	21
272	Does the European clinical trials directive really improve clinical trial approval time?. <i>British Journal of Clinical Pharmacology</i> , 2008 , 66, 546-50	3.8	19

271	Is the randomized controlled drug trial in Europe lagging behind the USA?. <i>British Journal of Clinical Pharmacology</i> , 2008 , 66, 774-80	3.8	4
270	Therapeutic resistance to angiotensin converting enzyme (ACE) inhibition is related to pharmacodynamic and -kinetic factors in 5/6 nephrectomized rats. <i>European Journal of Pharmacology</i> , 2008 , 580, 231-40	5.3	5
269	Immune modulation and graft protection by gene therapy in kidney transplantation. <i>European Journal of Pharmacology</i> , 2008 , 585, 261-9	5.3	9
268	A population-based screening for microalbuminuria among relatives of CKD patients: the Kidney Evaluation and Awareness Program in Sheffield (KEAPS). <i>American Journal of Kidney Diseases</i> , 2008 , 52, 434-43	7.4	21
267	Targeting proteinuria as a valid surrogate for individualized kidney protective therapy. <i>American Journal of Kidney Diseases</i> , 2008 , 51, 713-6	7.4	11
266	Extended prognostic value of urinary albumin excretion for cardiovascular events. <i>Journal of the American Society of Nephrology: JASN</i> , 2008 , 19, 1785-91	12.7	66
265	Cardiovascular and renal outcome in subjects with K/DOQI stage 1-3 chronic kidney disease: the importance of urinary albumin excretion. <i>Nephrology Dialysis Transplantation</i> , 2008 , 23, 3851-8	4.3	133
264	Albuminuria: a great risk marker, but an underestimated target in diabetes. <i>Diabetes Care</i> , 2008 , 31 Suppl 2, S190-3	14.6	8
263	Impact of the preintervention rate of renal function decline on outcome of renoprotective intervention. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008 , 3, 54-60	6.9	9
262	Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality. <i>American Journal of Epidemiology</i> , 2008 , 168, 897-905	3.8	184
261	Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. <i>Journal of the American Society of Nephrology: JASN</i> , 2008 , 19, 999-1007	12.7	258
260	ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2008 , 19, 771-9	12.7	63
259	Systemic gene therapy with interleukin-13 attenuates renal ischemia-reperfusion injury. <i>Kidney International</i> , 2008 , 73, 1364-73	9.9	30
258	Does the metabolic syndrome add to the diagnosis and treatment of cardiovascular disease?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008 , 5 Suppl 1, S10-4		17
257	Renal disease: a common and a silent killer. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008 , 5 Suppl 1, S27-35		7
256	Screening and monitoring for albuminuria: the performance of the HemoCue point-of-care system. <i>Kidney International</i> , 2008 , 74, 377-83	9.9	10
255	Gender differences in predictors of the decline of renal function in the general population. <i>Kidney International</i> , 2008 , 74, 505-12	9.9	87
254	Myocardial infarction does not further impair renal damage in 5/6 nephrectomized rats. <i>Nephrology Dialysis Transplantation</i> , 2008 , 23, 3103-10	4.3	30

253	Albuminuria: a target for treatment of type 2 diabetic nephropathy. <i>Seminars in Nephrology</i> , 2007 , 27, 172-81	4.8	47
252	Adenovirus-mediated interleukin-13 gene therapy attenuates acute kidney allograft injury. <i>Journal of Gene Medicine</i> , 2007 , 9, 1024-32	3.5	13
251	Trends in hyperlipidemia and hypertension management in type 2 diabetes patients from 1998-2004: a longitudinal observational study. <i>Cardiovascular Diabetology</i> , 2007 , 6, 25	8.7	17
250	Effect of first myocardial ischemic event on renal function. <i>American Journal of Cardiology</i> , 2007 , 100, 7-12	3	28
249	Metabolic syndrome: a fata morgana?. <i>Nephrology Dialysis Transplantation</i> , 2007 , 22, 15-20	4.3	22
248	Prolonged frozen storage of urine reduces the value of albuminuria for mortality prediction. <i>Clinical Chemistry</i> , 2007 , 53, 153-4	5.5	22
247	Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2007 , 18, 1540-6	12.7	225
246	What predicts progression and regression of urinary albumin excretion in the nondiabetic population?. <i>Journal of the American Society of Nephrology: JASN</i> , 2007 , 18, 637-45	12.7	31
245	Urinary pH affects albumin concentrations after prolonged frozen storage. <i>Nephrology Dialysis Transplantation</i> , 2007 , 22, 3670	4.3	8
244	Impact of weight change on albuminuria in the general population. <i>Nephrology Dialysis Transplantation</i> , 2007 , 22, 1619-27	4.3	64
243	Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2007 , 18, 1959-65	12.7	121
242	Change in albuminuria is predictive of cardiovascular outcome in normotensive patients with type 2 diabetes and microalbuminuria. <i>Diabetes Care</i> , 2007 , 30, 3119-21	14.6	21
241	Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies. <i>Journal of Hypertension</i> , 2007 , 25, 871-6	1.9	18
240	Claims in advertisements for antihypertensive drugs in a Dutch medical journal. <i>Journal of Hypertension</i> , 2007 , 25, 713-22	1.9	9
239	Apparent loss of urinary albumin during long-term frozen storage: HPLC vs immunonephelometry. <i>Clinical Chemistry</i> , 2007 , 53, 1520-6	5.5	36
238	Physicians' attitudes towards treatment guidelines: differences between teaching and nonteaching hospitals. <i>European Journal of Clinical Pharmacology</i> , 2006 , 62, 129-33	2.8	13
237	Endothelial function predicts the development of renal damage after combined nephrectomy and myocardial infarction. <i>Journal of the American Society of Nephrology: JASN</i> , 2006 , 17, S49-52	12.7	15
236	A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension. <i>Current Medical Research and Opinion</i> , 2006 , 22, 2095-100	2.5	6

235	Urinary albumin excretion as a predictor of the development of hypertension in the general population. <i>Journal of the American Society of Nephrology: JASN</i> , 2006 , 17, 331-5	12.7	92
234	Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. <i>Circulation</i> , 2006 , 113, 671-8	16.7	694
233	Evaluation of measures of urinary albumin excretion. <i>American Journal of Epidemiology</i> , 2006 , 164, 725-73.8		47
232	Early, but not late therapy with a vasopressin V1a-antagonist ameliorates the development of renal damage after 5/6 nephrectomy. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2006 , 7, 217-24	3	12
231	Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening. <i>Journal of the American Society of Nephrology: JASN</i> , 2006 , 17, 2582-90	12.7	151
230	Renal damage after myocardial infarction is prevented by renin-angiotensin-aldosterone-system intervention. <i>Journal of the American Society of Nephrology: JASN</i> , 2006 , 17, 3059-66	12.7	19
229	Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006 , 1, 761-7	6.9	133
228	Pharmacoeconomics of angiotensin II antagonists in type 2 diabetic patients with nephropathy: implications for decision making. <i>Pharmacoeconomics</i> , 2006 , 24, 523-35	4.4	18
227	Renoprotective effects of renin-angiotensin-system inhibitors. <i>Lancet, The</i> , 2006 , 367, 899-900; author reply 900-2	40	28
226	Microalbuminuria as an early marker for cardiovascular disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2006 , 17, 2100-5	12.7	258
225	Gansevoort et al. Respond to "Using Measures of Albumin Excretion" <i>American Journal of Epidemiology</i> , 2006 , 164, 731-732	3.8	
224	Microalbuminuria and endothelial dysfunction: emerging targets for primary prevention of end-organ damage. <i>Journal of Cardiovascular Pharmacology</i> , 2006 , 47 Suppl 2, S151-62; discussion S172-8	3.1	81
223	The role of angiotensin(1-7) in renal vasculature of the rat. <i>Journal of Hypertension</i> , 2006 , 24, 1971-8	1.9	37
222	Altered myogenic constriction and endothelium-derived hyperpolarizing factor-mediated relaxation in small mesenteric arteries of hypertensive subtotaly nephrectomized rats. <i>Journal of Hypertension</i> , 2006 , 24, 2215-23	1.9	25
221	Update on microalbuminuria as a biomarker in renal and cardiovascular disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2006 , 15, 631-6	3.5	56
220	Enhanced transduction of fibroblasts in transplanted kidney with an adenovirus having an RGD motif in the HI loop. <i>Kidney International</i> , 2006 , 69, 45-52	9.9	9
219	Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL. <i>Kidney International</i> , 2006 , 69, 1675-82	9.9	76
218	Endothelial dysfunction in chronic kidney disease: determinant of susceptibility to end-organ damage and therapeutic response. <i>Journal of Nephrology</i> , 2006 , 19, 246-58	4.8	32

217	Renoprotective therapy: is it blood pressure or albuminuria that matters?. <i>Lancet, The</i> , 2005 , 365, 913-4	4.0	8
216	Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. <i>American Heart Journal</i> , 2005 , 149, 408-13	4.9	97
215	The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial. <i>Journal of Hypertension</i> , 2005 , 23, 2055-61	1.9	28
214	The association between atherosclerotic risk factors and renal function in the general population. <i>Kidney International</i> , 2005 , 67, 1967-73	9.9	72
213	Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). <i>Kidney International</i> , 2005 , 67, 2089-100	9.9	2083
212	Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria. <i>Kidney International</i> , 2005 , S52-4	9.9	10
211	A report with consensus statements of the International Society of Nephrology 2004 Consensus Workshop on Prevention of Progression of Renal Disease, Hong Kong, June 29, 2004. <i>Kidney International</i> , 2005 , S2-7	9.9	26
210	The validity of screening based on spot morning urine samples to detect subjects with microalbuminuria in the general population. <i>Kidney International</i> , 2005 , S28-35	9.9	103
209	Renoprotection with and without blood pressure reduction. <i>Kidney International</i> , 2005 , S54-9	9.9	13
208	Prevention of chronic kidney and vascular disease: toward global health equity--the Bellagio 2004 Declaration. <i>Kidney International</i> , 2005 , S1-6	9.9	59
207	The kidney, a cardiovascular risk marker, and a new target for therapy. <i>Kidney International</i> , 2005 , S25-9	9.9	71
206	Uptake of angiotensin II receptor blockers in the treatment of hypertension. <i>European Journal of Clinical Pharmacology</i> , 2005 , 61, 461-6	2.8	6
205	Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. <i>Diabetologia</i> , 2005 , 48, 1980-7	10.3	32
204	Microalbuminuria and C-reactive protein: similar messengers of cardiovascular risk?. <i>Current Hypertension Reports</i> , 2005 , 7, 379-84	4.7	23
203	Beneficial effects of add-on hydrochlorothiazide in rats with myocardial infarction optimally treated with quinapril. <i>European Journal of Heart Failure</i> , 2005 , 7, 1085-94	12.3	4
202	Individual titration for maximal blockade of the renin-angiotensin system in proteinuric patients: a feasible strategy?. <i>Journal of the American Society of Nephrology: JASN</i> , 2005 , 16 Suppl 1, S53-7	12.7	23
201	Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. <i>Journal of the American Society of Nephrology: JASN</i> , 2005 , 16, 1775-80	12.7	31
200	Urinary albumin excretion and its relation with C-reactive protein and the metabolic syndrome in the prediction of type 2 diabetes. <i>Diabetes Care</i> , 2005 , 28, 2525-30	14.6	101

199	Letter regarding article by Klausen et al, "very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes". <i>Circulation</i> , 2005 , 111, e110-1; author reply e110-1	16.7	4
198	Does angiotensin (1-7) contribute to the anti-proteinuric effect of ACE-inhibitors. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2005 , 6, 96-101	3	13
197	Falsely low urinary albumin concentrations after prolonged frozen storage of urine samples. <i>Clinical Chemistry</i> , 2005 , 51, 2181-3	5.5	51
196	Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes. <i>Diabetes Care</i> , 2004 , 27, 1887-93	14.6	69
195	Dietary sodium restriction specifically potentiates left ventricular ACE inhibition by zofenopril, and is associated with attenuated hypertrophic response in rats with myocardial infarction. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2004 , 5, 27-32	3	8
194	Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. <i>Circulation</i> , 2004 , 110, 2809-16	16.7	401
193	C-reactive protein modifies the relationship between blood pressure and microalbuminuria. <i>Hypertension</i> , 2004 , 43, 791-6	8.5	74
192	Renal targeting of captopril using captopril-lysozyme conjugate enhances its antiproteinuric effect in adriamycin-induced nephrosis. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2004 , 5, 197-202	3	7
191	Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. <i>Journal of the American Society of Nephrology: JASN</i> , 2004 , 15, 3117-25	12.7	88
190	Low sodium modifies the vascular effects of angiotensin-converting enzyme inhibitor therapy in healthy rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004 , 310, 1183-9	4.7	8
189	Myocardial infarction enhances progressive renal damage in an experimental model for cardio-renal interaction. <i>Journal of the American Society of Nephrology: JASN</i> , 2004 , 15, 3103-10	12.7	69
188	The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. <i>Journal of Internal Medicine</i> , 2004 , 256, 1-14	10.8	239
187	Sodium intake affects urinary albumin excretion especially in overweight subjects. <i>Journal of Internal Medicine</i> , 2004 , 256, 324-30	10.8	159
186	Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. <i>Kidney International</i> , 2004 , 65, 1416-21	9.9	662
185	Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. <i>Kidney International</i> , 2004 , 65, 2309-20	9.9	685
184	Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment?. <i>Kidney International</i> , 2004 , S2-6	9.9	59
183	Trends in the incidence of treated end-stage renal failure in The Netherlands: hope for the future?. <i>Kidney International</i> , 2004 , S7-10	9.9	29
182	An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. <i>Kidney International</i> , 2004 , S18-21	9.9	132

181	Which method for quantifying urinary albumin excretion gives what outcome? A comparison of immunonephelometry with HPLC. <i>Kidney International</i> , 2004 , S69-75	9.9	54
180	Detecting and managing patients with type 2 diabetic kidney disease: proteinuria and cardiovascular disease. <i>Kidney International</i> , 2004 , S97-8	9.9	3
179	Approaches and methods in gene therapy for kidney disease. <i>Journal of Pharmacological and Toxicological Methods</i> , 2004 , 50, 13-24	1.7	23
178	Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. <i>Circulation</i> , 2004 , 110, 921-7	16.7	573
177	C-reactive protein and microalbuminuria differ in their associations with various domains of vascular disease. <i>Atherosclerosis</i> , 2004 , 172, 107-14	3.1	44
176	Impaired renal function in patients with ischemic and nonischemic chronic heart failure: association with neurohormonal activation and survival. <i>American Heart Journal</i> , 2004 , 148, 165-72	4.9	52
175	Should albuminuria be a therapeutic target in patients with hypertension and diabetes?. <i>American Journal of Hypertension</i> , 2004 , 17, 11S-15S; quiz A2-4	2.3	16
174	Angiotensin II receptor antagonist telmisartan in isolated systolic hypertension (ARAMIS) study: efficacy and safety of telmisartan 20, 40 or 80 mg versus hydrochlorothiazide 12.5 mg or placebo. <i>Journal of Hypertension</i> , 2004 , 22, 1033-7	1.9	21
173	Does comorbidity explain trends in prescribing of newer antihypertensive agents?. <i>Journal of Hypertension</i> , 2004 , 22, 2209-15	1.9	12
172	The abnormal renal vasodilator response to D1-like receptor stimulation in conscious SHR can be normalized by AT1 blockade. <i>Journal of Cardiovascular Pharmacology</i> , 2004 , 44, 571-6	3.1	4
171	Low sodium diet inhibits the local counter-regulator effect of angiotensin-(1-7) on angiotensin II. <i>Journal of Hypertension</i> , 2004 , 22, 2355-61	1.9	26
170	Drawbacks of the use of indirect estimates of renal function to evaluate the effect of risk factors on renal function. <i>Journal of the American Society of Nephrology: JASN</i> , 2004 , 15, 1316-22	12.7	47
169	Effect of losartan on microalbuminuria in normotensive patients with type 2 diabetes mellitus. A randomized clinical trial. <i>Annals of Internal Medicine</i> , 2003 , 139, 90-6	8	43
168	Role of proteinuria in the regulation of renal renin-angiotensin system components in unilateral proteinuric rats. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2003 , 4, 38-42	3	4
167	Endothelial dysfunction and infarct-size relate to impaired EDHF response in rat experimental chronic heart failure. <i>European Journal of Heart Failure</i> , 2003 , 5, 147-54	12.3	16
166	High dietary sodium blunts affects of angiotensin-converting enzyme inhibition on vascular angiotensin I-to-angiotensin II conversion in rats. <i>Journal of Cardiovascular Pharmacology</i> , 2003 , 42, 601-6	3.1	16
165	The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis. <i>Nephrology Dialysis Transplantation</i> , 2003 , 18, 2047-53	4.3	104
164	Effects of anti-proteinuric therapy with angiotensin-converting-enzyme inhibition on renal protein catabolism in the adriamycin-induced nephrotic rat. <i>Clinical Science</i> , 2003 , 105, 51-7	6.5	2

163	Best practice of hypertensive patients with kidney disease. <i>British Journal of Hospital Medicine</i> , 2003 , 64, 96-100		
162	A central body fat distribution is related to renal function impairment, even in lean subjects. <i>American Journal of Kidney Diseases</i> , 2003 , 41, 733-41	7.4	239
161	The reliability of different formulae to predict creatinine clearance. <i>Journal of Internal Medicine</i> , 2003 , 253, 563-73	10.8	46
160	Renoprotective effects of VPI versus ACEI in normotensive nephrotic rats on different sodium intakes. <i>Kidney International</i> , 2003 , 63, 64-71	9.9	15
159	C-reactive protein is associated with renal function abnormalities in a non-diabetic population. <i>Kidney International</i> , 2003 , 63, 654-61	9.9	165
158	The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. <i>Kidney International</i> , 2003 , 63, 1499-507	9.9	365
157	Myogenic constriction is increased in mesenteric resistance arteries from rats with chronic heart failure: instantaneous counteraction by acute AT1 receptor blockade. <i>British Journal of Pharmacology</i> , 2003 , 139, 1317-25	8.6	43
156	The COOPERATE trial. <i>Lancet, The</i> , 2003 , 361, 1055-6	4.0	5
155	Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. <i>Annals of Internal Medicine</i> , 2003 , 139, 244-52	8	758
154	Involvement of renal ACE activity in proteinuria-associated renal damage in untreated and treated adriamycin nephrotic rats. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2003 , 4, 106-12	3	13
153	Role of the endothelin-1 gene locus for renal impairment in the general nondiabetic population. <i>Journal of the American Society of Nephrology: JASN</i> , 2003 , 14, 2596-602	12.7	23
152	Cardiovascular risk factors are differently associated with urinary albumin excretion in men and women. <i>Journal of the American Society of Nephrology: JASN</i> , 2003 , 14, 1330-5	12.7	90
151	Coronary myogenic constriction antagonizes EDHF-mediated dilation: role of KCa channels. <i>Hypertension</i> , 2003 , 41, 912-8	8.5	19
150	Pharmacoeconomic aspects of losartan treatment to delay progression of renal disease in patients with Type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2003 , 4, 1543-50	4	2
149	Best practice for hypertensive patients with kidney disease. <i>British Journal of Hospital Medicine</i> , 2003 , 64, 96-100		
148	Addition of AT1 blocker fails to overcome resistance to ACE inhibition in adriamycin nephrosis. <i>Kidney International</i> , 2002 , 61, 473-80	9.9	21
147	Can angiotensin II be used for renoprotection?. <i>Kidney International</i> , 2002 , 61, 1176-7	9.9	2
146	Impaired coronary endothelial function in a rat model of spontaneous albuminuria. <i>Kidney International</i> , 2002 , 62, 181-91	9.9	29

145	Dual renin-angiotensin system blockade at optimal doses for proteinuria. <i>Kidney International</i> , 2002 , 62, 1020-5	9.9	129
144	The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus; a systematic review. <i>British Journal of Clinical Pharmacology</i> , 2002 , 53, 549P-550P	3.8	5
143	Renal targeting of captopril selectively enhances the intrarenal over the systemic effects of ACE inhibition in rats. <i>British Journal of Pharmacology</i> , 2002 , 136, 1107-16	8.6	10
142	Specific drug delivery to the kidney. <i>Cardiovascular Drugs and Therapy</i> , 2002 , 16, 489-96	3.9	34
141	Renoprotection: a matter of blood pressure reduction or agent-characteristics?. <i>Journal of the American Society of Nephrology: JASN</i> , 2002 , 13 Suppl 3, S202-7	12.7	11
140	D2-like receptor stimulation decreases effective renal plasma flow and glomerular filtration rate in spontaneously hypertensive rats. <i>Journal of Cardiovascular Pharmacology</i> , 2002 , 40, 35-42	3.1	0
139	Between-patient differences in the renal response to renin-angiotensin system intervention: clue to optimising renoprotective therapy?. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2002 , 3, 205-13	3	28
138	Targeting of captopril to the kidney reduces renal angiotensin-converting enzyme activity without affecting systemic blood pressure. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002 , 301, 1139-43	4.7	9
137	Endothelial dilatory function predicts individual susceptibility to renal damage in the 5/6 nephrectomized rat. <i>Journal of the American Society of Nephrology: JASN</i> , 2002 , 13, 2909-15	12.7	49
136	Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. <i>Circulation</i> , 2002 , 106, 1777-82	16.7	1170
135	Statins. <i>Journal of Hypertension</i> , 2002 , 20, 2351-2353	1.9	1
134	Optimal blood pressure control and antihypertensive regimens in hypertensive renal disease: the potential of exploring the mechanisms of response variability. <i>Current Opinion in Nephrology and Hypertension</i> , 2002 , 11, 135-40	3.5	7
133	Do severe systemic sequelae of proteinuria modulate the antiproteinuric response to chronic ACE inhibition?. <i>Nephrology Dialysis Transplantation</i> , 2002 , 17, 793-7	4.3	3
132	Targeting of doxorubicin to the urinary bladder of the rat shows increased cytotoxicity in the bladder urine combined with an absence of renal toxicity. <i>Journal of Drug Targeting</i> , 2002 , 10, 81-9	5.4	14
131	Normalization of aortic function during arousal episodes in the hibernating ground squirrel. <i>Life Sciences</i> , 2002 , 70, 2071-83	6.8	11
130	How to measure the prevalence of microalbuminuria in relation to age and gender?. <i>American Journal of Kidney Diseases</i> , 2002 , 40, 436-437	7.4	10
129	Enhanced responses of blood pressure, renal function, and aldosterone to angiotensin I in the DD genotype are blunted by low sodium intake. <i>Journal of the American Society of Nephrology: JASN</i> , 2002 , 13, 1025-1033	12.7	50
128	How to Attain Optimal Antiproteinuric Dose of Losartan in Non-Diabetic Patients with Nephrotic Range Proteinuria 2002 , 69-73		

127	Renal function as a predictor of prognosis in chronic heart failure. <i>Heart Failure Monitor</i> , 2002 , 2, 78-84		3
126	Delivery of Drugs and Antisense Oligonucleotides to the Proximal Tubular Cell of the Kidney Using Macromolecular and Pro-drug Approaches. <i>Methods and Principles in Medicinal Chemistry</i> , 2001 , 121-155 ^{0.4}		3
125	Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. <i>Kidney International</i> , 2001 , 60, 1131-40	9.9	267
124	Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. <i>Journal of Internal Medicine</i> , 2001 , 249, 519-26	10.8	469
123	Intracellular Angiotensin II and cell growth of vascular smooth muscle cells. <i>British Journal of Pharmacology</i> , 2001 , 132, 1590-6	8.6	36
122	Intracellular angiotensin II elicits Ca ²⁺ increases in A7r5 vascular smooth muscle cells. <i>European Journal of Pharmacology</i> , 2001 , 420, 9-18	5.3	18
121	Does a low-salt diet exert a protective effect on endothelial function in normal rats?. <i>Translational Research</i> , 2001 , 138, 200-5		6
120	Excessive urinary albumin levels are associated with future cardiovascular mortality in postmenopausal women. <i>Circulation</i> , 2001 , 103, 3057-61	16.7	119
119	Time course of the antiproteinuric and renal haemodynamic responses to losartan in microalbuminuric IDDM. <i>Nephrology Dialysis Transplantation</i> , 2001 , 16, 771-5	4.3	33
118	Intracellular angiotensin II: from myth to reality?. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2001 , 2, 219-26	3	20
117	ACE inhibition preserves heparan sulfate proteoglycans in the glomerular basement membrane of rats with established adriamycin nephropathy. <i>Nephron Experimental Nephrology</i> , 2001 , 9, 21-7		26
116	Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. <i>Annals of Internal Medicine</i> , 2001 , 135, 73-87	8	713
115	Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. <i>New England Journal of Medicine</i> , 2001 , 345, 861-9	59.2	5467
114	Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria. <i>American Journal of Kidney Diseases</i> , 2001 , 38, 1381-4	7.4	44
113	Intracellular angiotensin II inhibits heterologous receptor stimulated Ca ²⁺ entry. <i>Life Sciences</i> , 2001 , 70, 171-80	6.8	7
112	Potentials and limitations of the low-molecular-weight protein lysozyme as a carrier for renal drug targeting. <i>Renal Failure</i> , 2001 , 23, 397-409	2.9	27
111	Role of genetic variability in the renin-angiotensin system in diabetic and nondiabetic renal disease. <i>Seminars in Nephrology</i> , 2001 , 21, 580-92	4.8	9
110	Smoking is related to albuminuria and abnormal renal function in nondiabetic persons. <i>Annals of Internal Medicine</i> , 2000 , 133, 585-91	8	190

109	Renal hemodynamics in human hypertension. <i>Advances in Organ Biology</i> , 2000 , 9, 369-382		2
108	The antihypertensive and renal effects of angiotensin II receptor antagonists: remaining questions. <i>Current Opinion in Nephrology and Hypertension</i> , 2000 , 9, 57-61	3.5	11
107	Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. <i>Kidney International</i> , 2000 , 57, S32-S37	9.9	29
106	Angiotensin II receptor antagonist treatment lowers plasma total and very low + low density lipoprotein cholesterol in Type 1 diabetic patients with albuminuria without affecting plasma cholesterol esterification and cholesteryl ester transfer. <i>Diabetic Medicine</i> , 2000 , 17, 550-2	3.5	9
105	Comparison of zofenopril and lisinopril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE-inhibitors in experimental heart failure. <i>British Journal of Pharmacology</i> , 2000 , 130, 1999-2007	8.6	54
104	Low levels of urinary albumin excretion are associated with cardiovascular risk factors in the general population. <i>Clinical Chemistry and Laboratory Medicine</i> , 2000 , 38, 1107-10	5.9	39
103	Renal function, neurohormonal activation, and survival in patients with chronic heart failure. <i>Circulation</i> , 2000 , 102, 203-10	16.7	814
102	The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2000 , 1, 328-35	3	103
101	Direct interaction between the sympathetic and renin-angiotensin system in myocardial tissue: a microdialysis study in anaesthetised rats. <i>Journal of the Autonomic Nervous System</i> , 2000 , 78, 117-21		10
100	Chronic beta-blocker treatment in patients with advanced heart failure. Effects on neurohormones. <i>International Journal of Cardiology</i> , 2000 , 73, 7-12; discussion 13-4	3.2	29
99	Creatinine-based estimation of rate of long term renal function loss in lung transplant recipients. Which method is preferable?. <i>Journal of Heart and Lung Transplantation</i> , 2000 , 19, 256-62	5.8	31
98	Regulation of [Ca(2+)](i) homeostasis in MRP1 overexpressing cells. <i>FEBS Letters</i> , 2000 , 474, 107-10	3.8	8
97	Renal and systemic effects of continued treatment with renin inhibitor remikiren in hypertensive patients with normal and impaired renal function. <i>Nephrology Dialysis Transplantation</i> , 2000 , 15, 637-43	4.3	27
96	Urinary albumin excretion is associated with renal functional abnormalities in a nondiabetic population. <i>Journal of the American Society of Nephrology: JASN</i> , 2000 , 11, 1882-1888	12.7	228
95	Chronic angiotensin II infusion but not bradykinin blockade abolishes the antiproteinuric response to angiotensin-converting enzyme inhibition in established adriamycin nephrosis. <i>Journal of the American Society of Nephrology: JASN</i> , 2000 , 11, 490-496	12.7	13
94	A Comparison of Progression in Diabetic and Non-Diabetic Renal Disease: Similarity of Progression Promoters 2000 , 587-600		
93	Renin inhibition improves pressure natriuresis in essential hypertension. <i>Journal of the American Society of Nephrology: JASN</i> , 2000 , 11, 1813-1818	12.7	10
92	Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. <i>Kidney International</i> , 2000 , 57, 32-37	9.9	3

91	Direct vasodilating effects of the new dopaminergic agonist Z1046 in human arteries. <i>Journal of Cardiovascular Pharmacology</i> , 2000 , 35, 581-5	3.1	5
90	Long-term renal outcome after lung transplantation is predicted by the 1-month postoperative renal function loss. <i>Transplantation</i> , 2000 , 69, 1624-8	1.8	47
89	Angiotensin-(1-7) is a modulator of the human renin-angiotensin system. <i>Hypertension</i> , 1999 , 34, 296-301	3.5	156
88	Pretreatment renal vascular tone predicts the effect of specific renin inhibition on natriuresis in essential hypertension. <i>European Journal of Clinical Investigation</i> , 1999 , 29, 1019-26	4.6	6
87	Effect of proteinuria reduction on prevention of focal glomerulosclerosis by angiotensin-converting enzyme inhibition is modifiable. <i>Kidney International</i> , 1999 , 56, S42-S46	9.9	2
86	Contractile effects by intracellular angiotensin II via receptors with a distinct pharmacological profile in rat aorta. <i>British Journal of Pharmacology</i> , 1999 , 126, 1133-8	8.6	24
85	Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function. <i>European Journal of Clinical Pharmacology</i> , 1999 , 54, 953-8	2.8	20
84	Angiotensin-converting enzyme gene I/D polymorphism and renal disease. <i>Journal of Molecular Medicine</i> , 1999 , 77, 781-91	5.5	22
83	Dose of doxorubicin determines severity of renal damage and responsiveness to ACE-inhibition in experimental nephrosis. <i>Journal of Pharmacological and Toxicological Methods</i> , 1999 , 41, 69-73	1.7	18
82	Renoprotective therapy: titration against urinary protein excretion. <i>Lancet, The</i> , 1999 , 354, 352-3	4.0	95
81	Systemic factors are involved in the pathogenesis of proteinuria-induced glomerulosclerosis in adriamycin nephrotic rats. <i>Journal of the American Society of Nephrology: JASN</i> , 1999 , 10, 2359-66	12.7	31
80	Effect of proteinuria reduction on prevention of focal glomerulosclerosis by angiotensin-converting enzyme inhibition is modifiable. <i>Kidney International</i> , 1999 , 56, 42-46	9.9	7
79	Impaired renal vascular response to a D1-like receptor agonist but not to an ACE inhibitor in conscious spontaneously hypertensive rats. <i>Journal of Cardiovascular Pharmacology</i> , 1999 , 34, 191-8	3.1	21
78	A comparison of analytic procedures for measurement of fractional dextran clearances. <i>Translational Research</i> , 1998 , 132, 390-403		18
77	Sample dilution: a methodological pitfall in the measurement of tissue but not serum ace-activity. <i>Journal of Pharmacological and Toxicological Methods</i> , 1998 , 39, 45-9	1.7	9
76	Can continuous intraperitoneal infusion of 125I-iothalamate and 131I-hippuran be used for measurement of GFR in conscious rats?. <i>Renal Failure</i> , 1998 , 20, 249-55	2.9	1
75	Drug delivery to the kidneys and the bladder with the low molecular weight protein lysozyme. <i>Renal Failure</i> , 1998 , 20, 211-7	2.9	15
74	Renal targeting of a non-steroidal anti-inflammatory drug: effects on renal prostaglandin synthesis in the rat. <i>Clinical Science</i> , 1998 , 95, 603-9	6.5	10

73	A Comparison of Progression in Diabetic and Non-Diabetic Renal Disease: Similarity of Progression Promoters 1998 , 585-595		1
72	Proteinuria and progression of renal disease: therapeutic implications. <i>Current Opinion in Nephrology and Hypertension</i> , 1997 , 6, 133-40	3.5	23
71	Delta9-tetrahydrocannabinol activates [Ca ²⁺] _i increases partly sensitive to capacitative store refilling. <i>European Journal of Pharmacology</i> , 1997 , 336, R1-3	5.3	32
70	ACE-inhibitors: panacea for progressive renal disease. <i>Lancet, The</i> , 1997 , 349, 1852-3	4.0	34
69	A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. <i>Kidney International</i> , 1997 , 51, 793-7	9.9	151
68	A method for accurate measurement of GFR in conscious, spontaneously voiding rats. <i>Kidney International</i> , 1997 , 52, 244-7	9.9	12
67	Drug-targeting to the kidney: renal delivery and degradation of a naproxen-lysozyme conjugate in vivo. <i>Kidney International</i> , 1997 , 52, 1693-9	9.9	42
66	Urine collection in the freely moving rat: reliability for measurement of short-term renal effects. <i>Journal of Pharmacological and Toxicological Methods</i> , 1997 , 38, 47-51	1.7	13
65	Bioanalysis of captopril: two sensitive high-performance liquid chromatographic methods with pre- or postcolumn fluorescent labeling. <i>Biomedical Applications</i> , 1997 , 693, 181-9		43
64	Determination of dopaminergic prodrugs by high-performance liquid chromatography followed by post-column ion-pair extraction. <i>Biomedical Applications</i> , 1997 , 693, 484-8		1
63	Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy. <i>Lancet, The</i> , 1996 , 347, 94-5	4.0	133
62	The serum lathosterol to cholesterol ratio, an index of cholesterol synthesis, is not elevated in patients with glomerular proteinuria and is not associated with improvement of hyperlipidemia in response to antiproteinuric treatment. <i>Metabolism: Clinical and Experimental</i> , 1996 , 45, 723-30	12.7	10
61	ACE inhibitors and the kidney. A risk-benefit assessment. <i>Drug Safety</i> , 1996 , 15, 200-11	5.1	50
60	Antiproteinuric effect predicts renal protection by angiotensin-converting enzyme inhibition in rats with established adriamycin nephrosis. <i>Clinical Science</i> , 1996 , 90, 393-401	6.5	59
59	(Glyco)-protein drug carriers with an intrinsic therapeutic activity: The concept of dual targeting. <i>Journal of Controlled Release</i> , 1996 , 39, 163-172	11.7	18
58	Blood pressure reduction initiates the antiproteinuric effect of ACE inhibition. <i>Kidney International</i> , 1996 , 49, 174-80	9.9	6
57	Does the renin-angiotensin system determine the renal and systemic hemodynamic response to sodium in patients with essential hypertension?. <i>Hypertension</i> , 1996 , 27, 202-8	8.5	47
56	A Comparison of Progression in Diabetic and Non-Diabetic Renal Disease: Similarity of Progression Promoters 1996 , 551-559		

55	Drug-induced changes in renal hippurate clearance as a measure of renal blood flow. <i>Kidney International</i> , 1995 , 48, 1617-23	9.9	8
54	Proteinuria: a risk factor for pregnancy-related renal function decline in primary glomerular disease?. <i>American Journal of Kidney Diseases</i> , 1995 , 26, 187-92	7.4	11
53	Angiotensin II antagonism improves the lipoprotein profile in patients with nephrotic syndrome. <i>Journal of Hypertension</i> , 1995 , 13, S53-8	1.9	18
52	Renal and systemic effects of the renin inhibitor remikiren in patients with essential hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 1995 , 26, 39-45	3.1	12
51	Additive antiproteinuric effect of ACE inhibition and a low-protein diet in human renal disease. <i>Nephrology Dialysis Transplantation</i> , 1995 , 10, 497-504	4.3	144
50	Drug targeting to the kidney with low-molecular-weight proteins. <i>Advanced Drug Delivery Reviews</i> , 1994 , 14, 67-88	18.5	22
49	Discordant effects of enalapril and lisinopril on systemic and renal hemodynamics. <i>Clinical Pharmacology and Therapeutics</i> , 1994 , 56, 647-58	6.1	9
48	Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system?. <i>Kidney International</i> , 1994 , 45, 861-7	9.9	200
47	A general method for the determination of the kinetic stability of macrocyclic alkali-metal complexes with rates of decomplexation below 10^8 s ⁻¹ . <i>Journal of the Chemical Society Perkin Transactions II</i> , 1994 , 11-14		3
46	Functionalized Calixspherands: Synthesis and Peptide Coupling. <i>Journal of Organic Chemistry</i> , 1994 , 59, 972-976	4.2	19
45	Kinetically stable complexes of alkali cations with calixspherands: an evaluation of shielding. <i>Journal of the American Chemical Society</i> , 1994 , 116, 123-133	16.4	43
44	Have rational therapeutic principles emerged in treating hypertension in chronic renal failure?. <i>American Journal of Kidney Diseases</i> , 1993 , 21, 108-12	7.4	
43	Long-term benefits of the antiproteinuric effect of angiotensin-converting enzyme inhibition in nondiabetic renal disease. <i>American Journal of Kidney Diseases</i> , 1993 , 22, 202-6	7.4	86
42	Quantification of renal low-molecular-weight protein degradation in the intact rat. <i>Contributions To Nephrology</i> , 1993 , 101, 78-84	1.6	1
41	Quantification of renal low-molecular-weight protein handling in the intact rat. <i>Kidney International</i> , 1993 , 43, 949-54	9.9	28
40	Role of elevated lecithin: cholesterol acyltransferase and cholesteryl ester transfer protein activities in abnormal lipoproteins from proteinuric patients. <i>Kidney International</i> , 1993 , 44, 91-7	9.9	46
39	Dissociation between the course of the hemodynamic and antiproteinuric effects of angiotensin I converting enzyme inhibition. <i>Kidney International</i> , 1993 , 44, 579-84	9.9	45
38	Low molecular weight proteins as carriers for renal drug targeting: naproxen coupled to lysozyme via the spacer L-lactic acid. <i>Pharmaceutical Research</i> , 1993 , 10, 963-9	4.5	26

37	The antiproteinuric effects of blood pressure-lowering agents: differences between nondiabetics and diabetics. <i>Journal of Cardiovascular Pharmacology</i> , 1992 , 19 Suppl 6, S28-32	3.1	6
36	Atrial natriuretic factor influences renal diurnal rhythm in essential hypertension. <i>Hypertension</i> , 1992 , 20, 80-4	8.5	7
35	Management of chronic renal failure. <i>Current Opinion in Nephrology and Hypertension</i> , 1992 , 1, 116-23	3.5	
34	Accelerated progression of renal function loss after two pregnancies in a patient with proteinuria. <i>Lancet, The</i> , 1992 , 340, 183	4.0	1
33	Low molecular weight proteins as carriers for renal drug targeting. Preparation of drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates. <i>Journal of Medicinal Chemistry</i> , 1992 , 35, 1246-59	8.3	54
32	Differences in erythrocyte sodium transport between human plasma and artificial medium: the role and character of sodium efflux and influx stimulating plasma factors. <i>Clinica Chimica Acta</i> , 1992 , 213, 61-73	6.2	1
31	Influence of anaesthesia on renal hippurate handling during angiotensin-converting enzyme inhibition in unilateral renal artery stenosis. <i>American Journal of Nephrology</i> , 1992 , 12, 474-6	4.6	1
30	Renal specific delivery of sulfamethoxazole in the rat by coupling to the low molecular weight protein lysozyme via an acid-sensitive linker. <i>International Journal of Pharmaceutics</i> , 1992 , 80, R15-R19	6.5	12
29	Clearance of indomethacin occurs predominantly by renal glucuronidation. <i>Pharmaceutisch Weekblad</i> , 1992 , 14, 191-5		6
28	Additive antiproteinuric effect of angiotensin-converting enzyme inhibition and non-steroidal anti-inflammatory drug therapy: a clue to the mechanism of action. <i>Clinical Science</i> , 1991 , 81, 367-72	6.5	20
27	Low molecular weight proteins as carriers for renal drug targeting: naproxen-lysozyme. <i>Pharmaceutical Research</i> , 1991 , 8, 1223-30	4.5	39
26	Angiotensin II does not acutely reverse the reduction of proteinuria by long-term ACE inhibition. <i>Kidney International</i> , 1991 , 40, 734-41	9.9	37
25	The Antiproteinuric Effect of Angiotensin-Converting-Enzyme Inhibitors in Human Renal Disease 1991 , 95-113		1
24	Relief of renal artery stenosis: a tool to improve or preserve renal function in renovascular disease?. <i>Nephrology Dialysis Transplantation</i> , 1990 , 5, 481-8	4.3	10
23	Mechanism of the antiproteinuric effect of angiotensin-converting enzyme inhibition. <i>Contributions To Nephrology</i> , 1990 , 83, 160-5	1.6	7
22	Unilateral renal parenchymal disease with contralateral renal artery stenosis of the fibrodysplasia type. <i>Annals of Internal Medicine</i> , 1989 , 110, 437-45	8	8
21	Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. <i>Kidney International</i> , 1989 , 36, 272-9	9.9	261
20	Human plasma contains low molecular weight factors which stimulate active sodium transport in erythrocytes. <i>Clinica Chimica Acta</i> , 1989 , 179, 133-42	6.2	1

19	Angiotensin converting enzyme inhibitors and progressive renal insufficiency. Current experience and future directions. <i>Annals of Internal Medicine</i> , 1989 , 111, 503-16	8	121
18	Atrial natriuretic peptide-induced decreases in renal blood flow in man: implications for the natriuretic mechanism. <i>Clinical Science</i> , 1989 , 77, 55-60	6.5	15
17	A new constrictor device for external induction of a long-term stable and irreversible renal artery stenosis in the dog. <i>Pflugers Archiv European Journal of Physiology</i> , 1988 , 411, 688-91	4.6	1
16	Micro-HPLC and transfer techniques for directly measuring drug (indomethacin) transport across the isolated perfused renal proximal straight tubule. <i>Journal of Pharmacological Methods</i> , 1988 , 19, 275-82		1
15	Angiotensin converting enzyme inhibition improves diagnostic procedures for renovascular hypertension in dogs. <i>Hypertension</i> , 1988 , 12, 411-9	8.5	13
14	Angiotensin converting enzyme inhibition induces alterations to hippuran renography despite unchanged ipsilateral renal blood flow in conscious two-kidney, one clip Goldblatt hypertensive dogs. <i>Journal of Hypertension</i> , 1988 , 6, S455-7	1.9	3
13	Indomethacin secretion in the isolated perfused proximal straight rabbit tubule. Evidence for two parallel transport mechanisms. <i>Journal of Clinical Investigation</i> , 1988 , 81, 1585-92	15.9	5
12	Diuretic effects of angiotensin-converting enzyme inhibition: comparison of low and liberal sodium diet in hypertensive patients. <i>Journal of Cardiovascular Pharmacology</i> , 1987 , 9, 743-8	3.1	46
11	Preorganized macrocyclic ligands: a novel approach to functionalized hemispherands via aromatization. <i>Journal of Organic Chemistry</i> , 1987 , 52, 4913-4921	4.2	26
10	Reduction of proteinuria by angiotensin converting enzyme inhibition. <i>Kidney International</i> , 1987 , 32, 78-83	9.9	161
9	Moderate sodium restriction in hypertensive subjects: renal effects of ACE-inhibition. <i>Kidney International</i> , 1987 , 31, 815-9	9.9	48
8	Highly sensitive measurement of indomethacin using a high-performance liquid chromatographic technique combined with post-column in-line hydrolysis. <i>Biomedical Applications</i> , 1986 , 380, 157-62		14
7	Effects of nonsteroidal anti-inflammatory drugs on proteinuria. <i>American Journal of Medicine</i> , 1986 , 81, 84-94	2.4	73
6	Antiproteinuric effect of naproxen and indomethacin. A double-blind crossover study. <i>American Journal of Nephrology</i> , 1985 , 5, 236-42	4.6	30
5	Blood pressure response to enalaprilic acid in essential hypertension: dose-response and effect of pre-treatment with furosemide. <i>European Journal of Clinical Pharmacology</i> , 1985 , 29, 9-15	2.8	7
4	Pharmacological zero for electromagnetic renal blood flow measurement. <i>Pflugers Archiv European Journal of Physiology</i> , 1985 , 403, 220-1	4.6	5
3	Semi-micro method for the determination of cation flux rate constants in erythrocytes. <i>Clinica Chimica Acta</i> , 1985 , 150, 137-49	6.2	3
2	Nephroptosis and kidney function. <i>Nephron</i> , 1978 , 22, 366-73	3.3	11

- 1 Unilateral kidney blood flow measurement using the $^{81}\text{Rb}/^{81}\text{mKr}$ ratio. *Contributions To Nephrology*, **1978**, 11, 67-72

1.6 2